期刊文献+

芪参二莲汤加聚乙二醇干扰素α-2a联合利巴韦林治疗1b型慢性丙型肝炎疗效观察 预览 被引量:7

Efficacy of Qishen Erlian combined with pegylated interferon α-2a plus ribavirin in treatment of chronic hepatitis C genotype 1b patients
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:观察探讨PEG IFN(聚乙二醇干扰素)α-2a联合利巴韦林的基础上,加用芪参二莲汤治疗慢性丙型病毒性肝炎(CHC)的临床疗效。方法:选取我院2011年5月-2012年1月HCV RNA阳性的1b型CHC患者62例随机分为两组,治疗组30例,采用PEG IFNα-2a联合利巴韦林加芪参二莲汤治疗,对照组32例应用PEG IFNα-2a联合利巴韦林治疗,疗程48周,疗程结束后随访24周。并观察治疗前、后两组患者肝功能、HCV RNA及PBMC变化。结果:治疗组EVR为76.67%,ETVR为86.67%,随访SVR为83.33%;对照组分别为34.37%、50.00%、31.32%。两组病毒学应答比较,治疗组EVR、ETVR、SVR较对照组疗效显著,其差异均具有统计学意义(P〈0.05)。两组患者治疗48周后,ALT、TBil与本组治疗前比较,差异均具有统计学意义(P〈0.05),其中治疗组ALT与同组治疗前比较,差异具有显著意义(P〈0.01);两组患者治疗48周后,两组间同时段ALT及TBil比较,治疗组更优于对照组,差异均具有统计学意义(P〈0.05)。两组患者治疗48周后IL-10水平较本组治疗前均有所降低,差异均有统计学意义(P〈0.05);两组间治疗后48周同时段相比较,治疗组患者改善优于对照组,差异有统计学意义(P〈0.05),随访24周,两组间比较,差异仍具有统计学意义(P〈0.05)。治疗48后两组患者IL-12水平较本组治疗前比较差异均无统计学意义(P〉0.05),但随访24周显示,治疗组IL-12水平较同时段对照组比较,差异有统计学意义(P〈0.05)。结论:芪参二莲汤加PEG IFNα-2a联合利巴韦林治疗1b型CHC疗效显著,明显优于单用干扰素联合利巴韦林的临床疗效。不仅可以显著抑制HCV RNA复制,改善肝功能,而且可以减轻不良反应,预后良好稳定,值得临床推广。 Objective: To discuss the clinical efficacy of Qishen Erlian combined with pegylated interferon α-2a plus ribavirin in the treatment of chronic hepatitis C genotype 1b patients. Methods: Sixty-two HCV RNA 1b chronic hepatitis C positive patients in our hospital during May 2011 to January 2012 were randomly divided into two groups,the treatment group( n = 30),which were treated with Shenqi Erlian combined with PEG IFNα-2a plus ribavirin,the control group( n = 32) were treated with PEG IFNα-2a and ribavirin for 48 weeks. To observed the liver function,HCV-RNA and PBMC change before and after treatment,and also followed up for 24 weeks. Results: In the treatment group,EVR was 76. 67%,ETVR was 86. 67%,SVR was83. 33%; EVR was 34. 37%,ETVR was 50. 00% and SVR was 31. 32% in control group,effect was significant compared with the control group at virological response,the differences were statistically significant( P〈0.05). After 48 weeks' treatment,ALT,TBil was significant declined compared with the same group pre-treatment,the differences were statistically significant( P〈0.05),and ALT declined more significant in treatment group,the difference was significant( P 0. 01); compared with the control group after 48 weeks' treatment,the treatment group was better than the control group,the differences were statistically significant( P〈0.05). Both groups of patients after 48 weeks of treatment,IL-10 levels were decreased compared with pretreatment,the differences were statistically significant( P〈0.05); compared with the control group after 48 weeks' treatment,the treatment group was better than the control group,the differences were statistically significant( P〈0.05),followed up for24 weeks between the two groups,the difference was still statistically significant( P〈0.05). There was no statistically significant difference at IL-12 after 48 weeks' treatment( P〉0.05),compared with the control group,the level of IL-12 in treatment group was higher than the c
作者 王炳予 袁星星 张雅丽 WANG Bing-yu, YUAN Xing-xing , ZHANG Ya-li (Nangang Branch of Heilongiiang Sciences of TCM ( Haerbin Heilongfiang, 150001 ) China)
出处 《中西医结合肝病杂志》 2014年第4期217-219,238共4页 Chinese Journal of Integrated Traditonal and Western Medicine on Liver Diseases
关键词 芪参二莲汤 治疗应用 聚乙二醇干扰素Α-2A 治疗应用 利巴韦林 治疗应用 肝炎 丙型 慢性 病例对照研究 Qishen Erlian /therapeutic application pegylated interferon α-2a /therapeutic application ribavirin /therapeutic application chronic hepatitis C case-control studies
作者简介 通讯作者
  • 相关文献

参考文献14

二级参考文献58

共引文献12634

同被引文献65

引证文献7

二级引证文献19

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈